市場調査レポート

欧州の非血管ステント市場

European Markets for Nonvascular Stents

発行 Medtech Insight 商品コード 230644
出版日 ページ情報 英文 111 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
欧州の非血管ステント市場 European Markets for Nonvascular Stents
出版日: 2012年01月31日 ページ情報: 英文 111 Pages
概要

2010年、欧州の主要国(フランス・ドイツ・イタリア・スペイン・英国)では、56,550件以上の介入的手術において非血管ステントが使用され、手術に伴った関連製品の売上は約9,300万ドルの規模を記録しました。欧州での非血管ステント留置術の件数は、2015年には約65,790件に増加すると予測されており、それに伴った関連製品の売上は、年平均6.4%の成長率で推移し、2015年には1億2,600万ドルの規模に成長すると予測されています。

当レポートでは、欧州の主要国における非血管ステント市場について調査分析し、現在および新興の非血管ステント留置の関連技術・材料、適応疾患、製品区分/適応部位別の製品および技術、市場分析・予測(〜2015年)、競合分析、主要企業のプロファイルなどをまとめ、概略下記の構成でお届けいたします。

エグゼクティブサマリー

  • ステント設計
  • 手術件数
  • 市場分析
    • 胆管ステント
    • 食道ステント
    • 気管・気管支ステント
    • 泌尿器ステント
    • 総市場予測

第1章 現在および新興の末梢血管・非血管ステント留置技術

  • ステント設計
    • 血管ステント
    • 非血管ステント
    • ステント導入メカニズム
  • ステント材料
    • 金属
    • 一般的なポリマー
    • 生分解性ポリマー
  • ステントコーティング
    • 放射線不透過性強化
    • 生体親和性強化
    • 活性治療物質強化
  • ステント被覆・ライニング

第2章 非血管用途のためのステント留置:概要

  • 胆管疾患
    • 良性胆道狭窄
    • 悪性胆道狭窄
    • 治療
  • 食道疾患
    • 良性食道狭窄
    • 悪性食道狭窄
    • 治療
  • 腎疾患
    • 良性尿道・前立腺狭窄
    • 悪性尿道・前立腺狭窄
    • 治療
  • 気管・気管支疾患
    • 良性気管・気管支狭窄
    • 悪性気管・気管支狭窄
    • 治療

第3章 欧州の非血管ステント市場

  • 胆管ステント
    • 製品・技術
    • 市場分析
    • 競合分析
  • 食道ステント
    • 製品・技術
    • 市場分析
    • 競合分析
  • 気管・気管支ステント
    • 製品・技術
    • 市場分析
    • 競合分析
  • 泌尿器ステント
    • 製品・技術
      • 尿管ステント
      • 尿道(前立腺ステント)ステント
    • 市場分析
    • 競合分析
  • 総合市場分析
    • 成長推進因子
    • 成長阻害因子
    • 市場予測

第4章 企業プロファイル

  • Abbott Laboratories
  • C.R. Bard, Inc.
  • Boston Scientific Corporation
  • Cook Group, Inc.
  • ev3, Inc./Covidien, Inc.
  • W.L. Gore & Associates, Inc.
  • Johnson & Johnson
  • Medtronic, Inc.

付録

目次
Product Code: #A253

In recent years, there have considerable advances both in product design and materials used for all forms of nonvascular stents. Significant changes in the structure and design of nonvascular stents have been made through proprietary technologies, which have helped prevent stent migration and improve flexibility. In 2010, nonvascular stents (including biliary, esophageal, trachobronchial, and urologic) stents were used in more than 56,550 interventional procedures in the countries covered by this report (France, Germany, Italy, Spain, and the United Kingdom), generating nearly $93 million in associated product sales. Over the forecast period covered by this report, the number of nonvascular stenting procedures performed in Europe is expected to increase at a 3.1% growth rate, reaching nearly 65,790 in the year 2015; during the same period, corresponding dollar sales are expected to increase at a 6.4% growth rate, reaching approximately $126 million in the year 2015.

This new report by Medtech Insight includes analyses of products, technologies, current and forecast markets, competitors, and opportunities in the European nonvascular stents market. Major topics covered by this report include a discussion of current and emerging nonvascular stenting technologies; a clinical overview of nonvascular conditions targeted by stenting, and an analysis of the European markets for biliary, esophageal, tracheobronchial, and urologic (including ureteral and urethral/prostatic) stents.

Table of Contents

EXECUTIVE SUMMARY

  • i. Stent Design
  • ii. Procedure Volumes
  • iii. Market Analysis
    • a. Biliary Stents
    • b. Esophageal Stents
    • c. Tracheobronchial Stents
    • d. Urologic Stents
    • e. Combined Market Forecast
  • Exhibit ES-1: Europe, Nonvascular Stent Placements, Combined Procedure Volumes Forecast, 2010-2015
  • Exhibit ES-2: Europe, Nonvascular Stents, Combined Market Forecast, 2010-2015

1. CURRENT AND EMERGING PERIPHERAL VASCULAR AND NONVASCULAR STENTING TECHNOLOGIES

  • 1.1. Stent Design
    • 1.1.1. Vascular Stents
    • 1.1.2. Nonvascular Stents
    • 1.1.3. Stent Deployment Mechanisms
  • 1.2. Stent Materials
    • 1.2.1. Metal
      • 1.2.1.1. Absorbable Magnesium Alloys
      • 1.2.1.2. Cobalt Alloys
      • 1.2.1.3. Nickel-Titanium Alloys
      • 1.2.1.4. Stainless Steel
    • 1.2.2. Standard Polymers
    • 1.2.3. Biodegradable Polymers
  • 1.3. Stent Coatings
    • 1.3.1. Radiopacity Enhancement
    • 1.3.2. Biocompatibility Enhancement
    • 1.3.3. Active Therapeutic Enhancement
      • 1.3.3.1. Drug-Eluting Stents
        • 1.3.3.1.1. Antirestenotic Efficacy
        • 1.3.3.1.2. Drug Delivery Techniques
    • 1.3.4. Stent Coverings and Linings
  • Exhibit 1-1: Selected Biomedical, Clinical, and Technical Stent Requirements
  • Exhibit 1-2: Advantages and Disadvantages of Selected Vascular Stent Designs
  • Exhibit 1-3: Advantages and Disadvantages of Metal Stent Materials
  • Exhibit 1-4: Selected Polymeric Stent Materials
  • Exhibit 1-5: Selected Characteristics of Antirestenosis Agents Used in Drug-Eluting Stents
  • Exhibit 1-6: Advantages and Disadvantages of Nonresorbable and Biodegradable Polymeric Drug Carriers for Drug-Eluting Stents

2. OVERVIEW OF STENTING FOR NONVASCULAR APPLICATION

  • 2.1. Bile Duct Diseases
    • 2.1.1. Benign Biliary Strictures
    • 2.1.2. Malignant Biliary Strictures
    • 2.1.3. Treatment
  • 2.2. Esophageal Diseases
    • 2.2.1. Benign Esophageal Strictures
    • 2.2.2. Malignant Esophageal Strictures
    • 2.2.3. Treatment
      • 2.2.3.1. Nonsurgical Treatment
      • 2.2.3.2. Surgical Treatment
  • 2.3. Renal System Diseases
    • 2.3.1. Benign Urethral and Prostatic Strictures
    • 2.3.2. Malignant Urethral and Prostatic Strictures
    • 2.3.3. Treatment
  • 2.4. Tracheobronchial System Diseases
    • 2.4.1. Benign Tracheobronchial Strictures
    • 2.4.2. Malignant Tracheobronchial Strictures
    • 2.4.3. Treatment
      • 2.4.3.1. Expandable Metal Stents
      • 2.4.3.2. Silicone Stents

3. EUROPEAN NONVASCULAR STENTS MARKET

  • 3.1. Biliary Stents
    • 3.1.1. Products and Technologies
    • 3.1.2. Market Analysis
    • 3.1.3. Competitive Analysis
  • 3.2. Esophageal Stents
    • 3.2.1. Products and Technologies
    • 3.2.2. Market Analysis
    • 3.2.3. Competitive Analysis
  • 3.3. Tracheobronchial Stents
    • 3.3.1. Products and Technologies
    • 3.3.2. Market Analysis
    • 3.3.3. Competitive Analysis
  • 3.4. Urologic Stents
    • 3.4.1. Products and Technologies
      • 3.4.1.1. Ureteral Stents
      • 3.4.1.2. Urethral (or Prostatic) Stents
    • 3.4.2. Market Analysis
    • 3.4.3. Competitive Analysis
  • 3.5. Combined Market Analysis
    • 3.5.1. Market Drivers
    • 3.5.2. Market Limiters
    • 3.5.3. Combined Market Forecast
  • Exhibit 3-1: 2012, Europe, Selected Biliary Stents
  • Exhibit 3-2: Europe, Biliary Stent Placements, Procedure Volumes Forecast, 2010-2015
  • Exhibit 3-3: Europe, Biliary Stents, Market Forecast, 2010-2015
  • Exhibit 3-4: 2010, Europe, Biliary Stents Market, Share by Supplier
  • Exhibit 3-5: 2012, Europe, Selected Esophageal Stents
  • Exhibit 3-6: Europe, Esophageal Stent Placements, Procedure Volumes Forecast, 2010-2015
  • Exhibit 3-7: Europe, Esophageal Stents, Market Forecast, 2010-2015
  • Exhibit 3-8: 2010, Europe, Esophageal Stents Market, Share by Supplier
  • Exhibit 3-9: Advantages and Disadvantages of Metal and Silicone Tracheobronchial Stents
  • Exhibit 3-10: 2012, Europe, Selected Tracheobronchial Stents
  • Exhibit 3-11: Europe, Tracheobronchial Stent Placements, Procedure Volumes Forecast, 2010-2015
  • Exhibit 3-12: Europe, Tracheobronchial Stents, Market Forecast, 2010-2015
  • Exhibit 3-13: 2010, Europe, Tracheobronchial Stents Market, Share by Supplier
  • Exhibit 3-14: 2012, Europe, Selected Urologic Stents
  • Exhibit 3-15: Europe, Urologic Stent Placements, Procedure Volumes Forecast, 2010-2015
  • Exhibit 3-16: Europe, Urologic Stents, Market Forecast, 2010-2015
  • Exhibit 3-17: 2010, Europe, Urologic Stents Market, Share by Supplier
  • Exhibit 3-18: Europe, Nonvascular Stent Placements, Combined Procedure Volumes Forecast, 2010-2015
  • Exhibit 3-19: Europe, Nonvascular Stents, Combined Market Forecast, 2010-2015

4. COMPANY PROFILES

  • 4.1. Abbott Laboratories
  • 4.2. C.R. Bard, Inc.
  • 4.3. Boston Scientific Corporation
  • 4.4. Cook Group, Inc.
  • 4.5. ev3, Inc./Covidien, Inc.
  • 4.6. W.L. Gore & Associates, Inc.
  • 4.7. Johnson & Johnson
  • 4.8. Medtronic, Inc.

APPENDIX: COMPANY LISTING

Back to Top